Table 1.
Baseline demographics
| SII ≤ 1449(n = 78) | SII>1449(n = 46) | P | |
|---|---|---|---|
| Age (years) | 55 (48, 64) | 55 (48, 66) | 0.49 |
| Gender, n (%) | 0.23 | ||
| male | 54 (69.2) | 27 (58.7) | |
| female | 24 (30.8) | 19 (41.3) | |
| Concomitant disorders, n (%) | |||
| CAD | 2 (2.7) | 3 (6.5) | 0.36 |
| Hypertension | 54 (69.2) | 36 (78.3) | 0.28 |
| Diabetes | 2 (2.7) | 4 (8.7) | 0.19 |
| CKD | 3 (3.8) | 3 (6.5) | 0.67 |
| Cerebrovascular disease | 5 (6.4) | 2 (4.3) | 1.00 |
| Smoking | 40 (51.3) | 15 (32.6) | 0.04 |
| Laboratory results | |||
| D-dimer | 1890 (1200, 3800) | 3650 (1870, 7115) | 0.07 |
| C reactive protein | 69 ± 60 | 109 ± 88 | 0.04 |
| PLT(×10*9/L) | 207 ± 82 | 260 ± 79 | 0.01 |
| NEUT(×10*9/L) | 7.3 ± 2.5 | 10.7 ± 3.9 | < 0.01 |
| LYMPH(×10*9/L) | 1.8 ± 1.2 | 1.2 ± 0.5 | 0.01 |
| SII | 885 ± 322 | 2803 ± 2001 | < 0.01 |
| Imaging results | |||
| MAD in lesion (mm) | 38 ± 9 | 40 ± 9 | 0.46 |
| Debakey III | 0.29 | ||
| IIIa | 16 (20.5) | 6 (13.0) | |
| IIIb | 62 (79.5) | 40 (87.0) | |
| FL status | 0.93 | ||
| patent | 27 (34.6) | 17 (37.0) | |
| partial thrombogenesis | 35 (44.9) | 19 (41.3) | |
| thrombogenesis | 16 (20.5) | 10 (21.7) | |
| Oral medication for discharge | |||
| β blocker | 58 (74.3) | 41 (89.1) | < 0.05 |
| Alpha blocker | 18 (23.1) | 13 (28.3) | 0.52 |
| ACEI/ARB | 61 (78.2) | 34 (73.9) | 0.59 |
| CCB | 56 (71.8) | 36 (78.3) | 0.43 |
| hydragogue | 26 (33.3) | 11 (23.9) | 0.27 |
| statin | 22 (29.2) | 18 (39.1) | 0.21 |
AAA: abdominal aortic aneurysm; PLT: platelet; NEUT: neutrophile; LYMPH: lymphocyte; FL: false lemon; MAD: maximum aortic diameter; CAD: coronary artery disease; CKD: chronic renal disease; ACEI/ARB: angiotensin converting enzyme inhibitors/ angiotensin II receptor blockers; CCB: calcium channel blocker